Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.41 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.41 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CTSV | O60911 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5859014 | 0.91 | LMNA (0.45) | PTGER1MEN1KMT2APTGER4PTGER3 | |
| SCHEMBL6095629 | 0.83 | FOLH1 (0.55) | PTGER1MEN1KMT2AMRGPRX4PTGER4 | |
| SCHEMBL6094860 | 0.82 | KDM4E (0.52) | MRGPRX4CYP2C9TDP1APEX1LMNA | |
| SCHEMBL5859062 | 0.81 | BCHE (0.42) | PTGER1PTGER4PTGER3PTGER2MAPT | |
| SCHEMBL1169607 | 0.81 | TSHR (0.51) | PTGER1MEN1KMT2APTGER4PTGER3 | |
| SCHEMBL6096263 | 0.80 | HMGB1 (0.46) | KMT2AMRGPRX4MAPTCYP2C9SMN1; SMN2 | |
| SCHEMBL27596107 | 0.80 | ALDH1A1 (0.52) | PTGER1MEN1KMT2AMRGPRX4NPC1 | |
| SCHEMBL27578074 | 0.80 | PTGER1 (0.50) | PTGER1CTSVCTSLMAPTCYP2C9 | |
| SCHEMBL27579891 | 0.80 | PTGER1 (0.50) | PTGER1MEN1KMT2AMRGPRX4CTSV | |
| SCHEMBL5859872 | 0.78 | MCL1 (0.53) | PTGER1MRGPRX4CTSVCTSLMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7064124-B2 | NF-κB inhibitor containing substituted benzoic acid derivative as active ingredient | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2006-06-20 | — | — | US | claimed |
| US-7122543-B2 | Substituted benzoic acid derivatives having NF-κB inhibiting action | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2006-10-17 | — | — | US | disclosed |
| US-7064124-B2 | NF-κB inhibitor containing substituted benzoic acid derivative as active ingredient | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2006-06-20 | — | — | US | disclosed |
| EP-1437339-A1 | SUBSTITUTED BENZOIC ACID DERIVATIVES EXHIBITING NF-KAPPA B INHIBITING ACTIVITY | Daiichi Suntory Pharma Co., Ltd. (JP) | 2004-07-14 | — | — | EP | disclosed |
| US-20040122244-A1 | Nf-kappa b inhibitor containing substituted benzoic acid derivative as active ingredient | DAIICHI ASUBIO PHARMA CO., LTD. (JP) | 2004-06-24 | — | — | US | disclosed |
| US-20040039061-A1 | Substituted benzoic acid derivatives exhibiting nf-k b inhibiting activity | DAIICHI ASUBIO PHARMA CO., LTD. (JP) | 2004-02-26 | — | — | US | disclosed |
| CN-1460097-A | NF-kB inhibitor containing substituted benzoic acid derivative as active ingredient | DAIICHI SUNTORY SEIYAKU CO LTD (JP) | 2003-12-03 | — | — | CN | disclosed |
| EP-1314712-A1 | NF-KAPPA-B INHIBITOR CONTAINING SUBSTITUTED BENZOIC ACID DERIVATIVE AS ACTIVE INGREDIENT | Daiichi Suntory Pharma Co., Ltd. (JP) | 2003-05-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122244-A1 | Nf-kappa b inhibitor containing substituted benzoic acid derivative as active ingredient | NFKBIA, NFKB1, IKBKB | PTGER1 1847/4885MEN1 4600/4885KMT2A 2280/4885 |
| US-20040039061-A1 | Substituted benzoic acid derivatives exhibiting nf-k b inhibiting activity | NFKBIA, NFKB2, IKBKB | PTGER1 1730/4885MEN1 4230/4885KMT2A 1845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.